Cargando…
Case Report: A Rare Case of Pembrolizumab-Induced Bullous Pemphigoid
The programmed cell death protein 1 inhibitor pembrolizumab, an immune checkpoint inhibitor, has subsequently been approved for the treatment of a wide variety of malignant tumors. Compared with conventional chemotherapy, immunotherapy is associated with a unique set of immune reactions, known colle...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477373/ https://www.ncbi.nlm.nih.gov/pubmed/34594337 http://dx.doi.org/10.3389/fimmu.2021.731774 |